Northwestern University Human Resources

NVG-291, an injectable peptide drug, demonstrated significant mobility improvements in a phase 2 trial for spinal cord injury patients, with one participant reducing his 10-meter walk time from 45 to 15 seconds.

Northwestern University researchers have developed lipid nanoparticle spherical nucleic acids (LNP-SNAs) that deliver CRISPR gene-editing tools up to three times more effectively than standard methods.

Northwestern Medicine researchers discovered that Zileuton, an FDA-approved asthma drug, nearly eliminated life-threatening allergic reactions in mice by blocking a previously unknown pathway involving the DPEP1 gene.

A Nature study led by MD Anderson researchers found that ovarian cancer patients with PPP2R1A mutations had significantly better overall survival when treated with immune checkpoint blockade therapy.

Prometheus Laboratories launched PredictrPK VDZ and PredictrPK UST, precision-guided dosing tests for vedolizumab and ustekinumab in IBD patients, expanding their platform to cover four major biologics.

The TRUST trial, the first phase III randomized study comparing surgical timing in advanced ovarian cancer, demonstrated statistically significant improvement in progression-free survival with primary cytoreductive surgery versus interval surgery (22.1 vs 19.7 months, HR=0.80, P=.018).

The FDA approved an expanded indication for Sanofi's MenQuadfi meningococcal vaccine to include children aged 6 weeks to 23 months, making it the only MenACWY vaccine with no upper age limit.

Scientists have developed the first wireless device capable of remotely activating photoactivable drugs, demonstrating effective pain management using photolabile morphine without typical opioid side effects.

Northwestern University researchers screened nearly 500 FDA-approved compounds and identified piperacillin as a potentially more effective Lyme disease treatment than current standard doxycycline therapy.

Grove Biopharma, a Northwestern University spinout developing therapies for intracellular disease targets, has secured $30 million in Series A financing to fuel its expansion and research initiatives.